Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Beijing Succeeder TechnologySHSE:688338 -4.01%89 3-Year ROIIC % is 0.54 as of Dec. 2025, which is 94% below its 10-year median of 9.68. GuruFocus rates SHSE:688338 with a GF Score™ of 89/100 and a GF Value™ of ¥24.17 (Modestly Overvalued). The stock has 4 warning signs investors should review. Among 795 Medical Devices & Instruments companies, Beijing Succeeder Technology ranks worse than 51.32% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Beijing Succeeder Technology's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was 0.54%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
SHSE:688338's 3-Year ROIIC % is ranked worse than 51.32% of 795
companies
in the Medical Devices & Instruments industry
Industry Median: 1.47
vs SHSE:688338: 0.54
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Beijing Succeeder Technology 3-Year ROIIC % Related Terms
Beijing Succeeder Technology 3-Year ROIIC % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:688338 vs ABT, SYK, MDT: 3-Year ROIIC % Comparison
For the Medical Devices subindustry, Beijing Succeeder Technology's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Beijing Succeeder Technology 3-Year ROIIC % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Beijing Succeeder Technology's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Beijing Succeeder Technology's 3-Year ROIIC % falls into.
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( 73.126396 (Dec. 2025) - 72.012546 (Dec. 2022) )
/
( 442.498 (Dec. 2025) - 236.683 (Dec. 2022) )
=
1.11385
/
205.815
=
0.54%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Beijing Succeeder Technology (SHSE:688338) has a 3-Year ROIIC % of 0.54 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Beijing Succeeder Technology and its competitors. This is 94% below median its historical median of 9.68. Over the past decade, Beijing Succeeder Technology's 3-Year ROIIC % has ranged from 0.54 to 210.15. According to the industry distribution chart, Beijing Succeeder Technology ranks #408 out of 795 companies in the Medical Devices & Instruments industry, placing it in the top 51.3%.
Is Beijing Succeeder Technology's 3-Year ROIIC % too high?
Beijing Succeeder Technology's current 3-Year ROIIC % of 0.54 is 94% below median its 10-year median of 9.68. Over the past 10 years, this metric has ranged from a low of 0.54 to a high of 210.15. The Medical Devices & Instruments industry median 3-Year ROIIC % is 1.47. Beijing Succeeder Technology's value of 0.54 is 63.3% below this industry median. Based on the distribution chart, Beijing Succeeder Technology ranks #408 out of 795 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Beijing Succeeder Technology has a GF Score™ of 89/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Beijing Succeeder Technology's 3-Year ROIIC % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Beijing Succeeder Technology ranks #408 out of 795 companies for 3-Year ROIIC %. This places Beijing Succeeder Technology in the lower half of its industry. The industry median 3-Year ROIIC % is 1.47. Beijing Succeeder Technology's value of 0.54 is 63.3% below this benchmark. Historically, Beijing Succeeder Technology's own 3-Year ROIIC % has ranged from 0.54 to 210.15 over the past decade. While the company's 10-year median is 9.68 vs. the industry median of 1.47, Beijing Succeeder Technology has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Medical Devices & Instruments company?
The median 3-Year ROIIC % among Medical Devices & Instruments companies is 1.47, based on 795 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Beijing Succeeder Technology's current 3-Year ROIIC % of 0.54 is 63.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Beijing Succeeder Technology and its competitors. For the Medical Devices & Instruments industry, the median 3-Year ROIIC % is 1.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Beijing Succeeder Technology's current 3-Year ROIIC % is 0.54, which is 94% below median its own 10-year median of 9.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beijing Succeeder Technology stock overvalued right now?
Based on GuruFocus' analysis, Beijing Succeeder Technology (SHSE:688338) is currently considered Modestly Overvalued. The stock's GF Value™ is ¥24.17, compared to a current price of ¥29.24 — trading 21% above its estimated fair value. The current 3-Year ROIIC % is 0.54, which is 94% below median its 10-year median of 9.68 and 63.3% below the Medical Devices & Instruments industry median of 1.47. Beijing Succeeder Technology's overall GF Score™ is 89/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Beijing Succeeder Technology (SHSE:688338), the current 3-Year ROIIC % is 0.54 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Beijing Succeeder Technology (SHSE:688338) Overvalued in 2026?
Based on GuruFocus' analysis, Beijing Succeeder Technology stock appears to be overvalued.
The current stock price of ¥29.24 is trading 21% above its estimated GF Value™ of ¥24.17.
GuruFocus considers Beijing Succeeder Technology to be Modestly Overvalued.
Key valuation signals for SHSE:688338:
3-Year ROIIC %: 0.54 (94% below median its 10-year median of 9.68)
GF Value™: ¥24.17 vs. price of ¥29.24 (21% above fair value)
Industry Position: 63.3% below the Medical Devices & Instruments median (#408 of 795)
No single metric tells the full story. See the SHSE:688338 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Beijing Succeeder Technology Inc is engaged in production and sales of detection instruments, reagents and consumables in the field of in vitro diagnosis of thrombosis and hemostasis. The company develops, manufactures and sells in-vitro diagnostic products including coagulation analyzers and reagents, blood rheology analyzers, ESR analyzers and platelet aggregation analyzers. Its product portfolio includes Fully Auto Coagulation Analyzer; Semi Auto Coagulation Analyzer; ESR Analyzer; Platelet Aggregation Analyzer; and Coagulation Reagents.
89GF Score
Get the complete analysis for SHSE:688338
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688338 has been successfully added to your 
